Morphine Nursing Considerations and Patient Teaching [Drug Guide]

What is Morphine?

Morphine is a potent opioid analgesic for moderate to severe pain. It acts on the CNS by binding opioid receptors, primarily the mu-opioid receptors in the brain and spinal cord, which reduces the perception of pain and alters the emotional response to it. It is used after surgery or trauma, in cancer pain, and in palliative and end-of-life care.

Generic Name

morphine. The active ingredient is the same whether it is formulated as morphine sulfate, morphine hydrochloride, or any other salt.

Brand Names

MS Contin, MS Contin SRT, Astramorph, Doloral, Kadian, Avinza, Oramorph SR, Roxanol, Duramorph, Morphine Sulfate ER, Embeda, Arymo ER, Infumorph, M-Eslon, Morphabond ER, Morphine EPD, Morphine Extra Forte, Morphine Forte, Morphine HP, Morphine LP Epidural, M.O.S., M.O.S.-SR, and Statex.

Drug Classification

• Therapeutic class: opioid analgesics
• Pharmacologic class: opioid agonists

Indications and Therapeutic Effects

Morphine is primarily indicated for moderate to severe pain. Its effects:

1. Pain relief. Binds opioid receptors in the brain and spinal cord, reducing pain perception.
2. Analgesia. Effective for acute and chronic pain, including postoperative, cancer, traumatic, and terminal-illness pain.
3. Sedation. Induces relaxation and sedation, useful in severe pain and distress.
4. Anxiolysis. Eases anxiety tied to pain.
5. Cough suppression. Antitussive effect, sometimes used for severe, disruptive coughing.
6. Dyspnea relief. In palliative care, relieves dyspnea in advanced respiratory disease or end-of-life care.

Mechanism of Action

Morphine binds mu-opioid receptors and inhibits neurotransmitter release, modulates neuronal excitability, and activates reward pathways, producing pain relief, sedation, and potential euphoria.

1. Opioid receptor binding. Binds mu-opioid receptors (G-protein-coupled) in the periaqueductal gray matter, spinal cord dorsal horn, and brainstem.
2. Inhibition of neurotransmitter release. Inhibits release of substance P, GABA, and glutamate, reducing transmission of pain signals.
3. Activation of G-protein pathways. Inhibits adenylyl cyclase (lowering cAMP) and opens potassium channels, hyperpolarizing neurons and reducing excitability.
4. Inhibition of nociceptive transmission. Reduces pain perception and alters the emotional response to pain.
5. Activation of reward pathways. Activates the mesolimbic dopamine system, producing euphoria, which drives its abuse and addiction potential.
6. Central and peripheral effects. Acts centrally on pain processing and peripherally in the GI tract, where reduced gut motility causes constipation.

Precautions and Contraindications

Precautions

1. Respiratory depression. Higher with large doses or with other respiratory depressants (benzodiazepines, alcohol). Monitor closely and adjust the dose.
2. Sedation and impaired alertness. Hold off on driving or machinery until the patient knows how morphine affects them.
3. Hypotension. Especially in hypovolemic patients or those with cardiovascular disease. Monitor blood pressure.
4. Constipation. Common from slowed gut motility. Maintain hydration, fiber, and regular bowel movements; laxatives or stool softeners may be ordered prophylactically.
5. Physical dependence and withdrawal. Prolonged use causes dependence; taper gradually to avoid withdrawal.

Contraindications

1. Hypersensitivity. Known allergy to morphine or other opioids, given the risk of anaphylaxis.
2. Respiratory insufficiency. Severe cases such as ARDS or severe COPD, since morphine further suppresses respiratory function.
3. Paralytic ileus. Morphine worsens bowel obstruction and can lead to perforation.
4. Acute alcohol intoxication. Potentiates CNS depression, risking severe respiratory depression, coma, or death.
5. Head injury or increased ICP. Depresses respiratory drive and can worsen cerebral edema.
6. MAOIs. Do not use with MAOIs or within 14 days of stopping them, given the risk of serotonin syndrome (hyperthermia, agitation, altered mental status).

Drug Interactions

Drug-Drug

1. CNS depressants (benzodiazepines, barbiturates, sedatives, hypnotics, alcohol): potentiate sedation and respiratory depression, risking coma or death.
2. MAOIs: increased risk of serotonin syndrome (hyperthermia, agitation, confusion, tremors, diaphoresis). Avoid or monitor closely.
3. Tricyclic antidepressants (TCAs): enhance analgesia but increase respiratory depression and CNS depression. Monitor closely.
4. SSRIs and SNRIs: increased risk of serotonin syndrome. Monitor for signs and symptoms.
5. Anticholinergics (antimuscarinics, antispasmodics): increased constipation. Manage with laxatives or stool softeners.
6. Antihypertensives: potentiate hypotension, risking cardiovascular collapse. Monitor blood pressure and adjust doses.
7. Anticoagulants (such as warfarin): increased bleeding risk. Monitor and adjust anticoagulant dosing.
8. CYP450 inhibitors and inducers: alter morphine metabolism and plasma levels. Examples: fluoxetine (CYP2D6 inhibitor), rifampin (CYP3A4 inducer).
9. GI motility agents (such as metoclopramide): alter morphine absorption and distribution.
10. Antiemetics (ondansetron, promethazine): enhance sedation and respiratory depression. Monitor CNS and respiratory status.

Drug-Natural Products

1. St. John’s Wort. Induces CYP3A4 and CYP2C9, speeding metabolism and lowering morphine levels and efficacy.
2. Grapefruit juice. Inhibits intestinal CYP3A4, raising systemic morphine exposure and side effects (sedation, respiratory depression).
3. Kratom. Contains mu-opioid agonist alkaloids; adds to respiratory depression, sedation, and dependence.
4. Valerian root. Sedative; potentiates CNS and respiratory depression.
5. Kava kava. CNS depressant; enhances sedation. Avoid or monitor closely.
6. Chamomile. Sedative compounds; increase CNS and respiratory depression.
7. Passionflower. Sedative; enhances CNS and respiratory depression.
8. CBD products. May inhibit metabolizing enzymes and modulate opioid receptors; effects are not well studied. Use caution.
9. Cannabis. Cannabinoids may potentiate analgesia but add to CNS and respiratory depression.

Drug-Food

1. Grapefruit juice. Inhibits intestinal CYP3A4, raising morphine exposure and side effects.
2. High-fat meals. Delay absorption and onset. Take on an empty stomach or with a light meal.
3. Fiber-rich foods. Delay gastric emptying and may slow absorption. Keep fiber intake consistent.
4. Alcohol. Enhances sedation and CNS and respiratory depression. Avoid.
5. Tyramine-rich foods (aged cheeses, cured meats, fermented products): can trigger hypertensive crisis in patients on MAOIs and morphine.
6. Caffeine. May enhance analgesia but add CNS stimulation and agitation.
7. Calcium-rich foods (dairy, fortified beverages): can interfere with absorption. Separate intake by a few hours.
8. Ginger. May enhance pain relief but add to CNS depression. Monitor.
9. Turmeric. Curcumin may enhance analgesia but increase bleeding risk through platelet effects.
10. Licorice. Glycyrrhizin inhibits morphine metabolism, prolonging half-life and raising toxicity risk.

Adverse Effects

Common Side Effects

1. Nausea and vomiting. Common at initiation or dose increase; may ease with continued use or antiemetics.
2. Constipation. From slowed GI motility. Maintain hydration, fiber, and activity; laxatives or stool softeners as needed.
3. Sedation and drowsiness. Hold driving and machinery until the effect is known.
4. Dizziness and lightheadedness. Worse on standing. Change positions slowly to prevent falls.
5. Respiratory depression. Serious at high doses or in opioid-naive patients: decreased rate, shallow breathing, hypoxemia. Monitor closely at initiation and dose changes.

Less Common Side Effects

1. Pruritus. From histamine release or allergic reaction. Antihistamines may help.
2. Urinary retention. From reduced bladder contractility and increased sphincter tone. Intermittent catheterization may be needed.
3. Confusion and delirium. More likely in elderly patients or those with cognitive impairment. Monitor and adjust the dose.

Adverse Effects

1. Hypotension. Especially in hypovolemic or cardiovascular patients. Monitor blood pressure.
2. Physical dependence and withdrawal. Taper gradually when discontinuing.
3. Tolerance. Analgesic tolerance can develop, requiring higher doses. Monitor and adjust.
4. Addiction and misuse. High potential, especially with a history of substance abuse. Assess risk and monitor for diversion.
5. Serotonin syndrome. With serotonergic drugs: hyperthermia, agitation, confusion, tremors, diaphoresis. Avoid or monitor closely.
6. Anaphylaxis. Rare. Watch for rash, itching, swelling, or difficulty breathing.

Serious Adverse Effects

1. Severe respiratory depression. At high doses or in opioid-naive patients. Reverse with naloxone, an opioid antagonist.
2. Cardiac arrest. Rare bradycardia or arrest, especially with cardiac disease or other cardiac-depressant drugs.
3. GI perforation. Chronic use raises GI complication risk, especially with pre-existing GI disorders or concurrent NSAIDs or corticosteroids.

Administration Considerations

Available Forms

1. Oral tablets/capsules. Immediate-release (IR) for rapid relief; extended-release (ER) for around-the-clock control with less frequent dosing.
2. Oral solutions/suspensions. For patients who cannot swallow tablets; common in pediatric and elderly populations.
3. Oral concentrate. Highly concentrated liquid for higher doses or for patients who cannot swallow large volumes.
4. Oral immediate-release solution. Fast onset for patients who cannot take other oral forms or need rapid relief.
5. Intravenous (IV) injection. Rapid relief in acute settings such as postoperative pain or trauma.
6. Subcutaneous injection. Alternative route when oral is not tolerated or IV access is difficult.
7. Rectal suppositories. Systemic absorption through the rectal mucosa; used in palliative care or with severe pain or nausea.
8. Transdermal patch. Continuous, around-the-clock control for chronic pain.
9. Epidural injection. Regional anesthesia or analgesia for surgery or chronic pain.

Dosage for Neonates

• IM, IV, Subcut (Neonates): 0.05 mg/kg q 4 – 8 hr, maximum dose: 0.1 mg/kg. Use preservative-free formulation.
• IV (Neonates): Continuous infusion, 0.01 – 0.03 mg/kg/hr.

Dosage for Children

• PO, Rect (Children <50 kg): Usual starting dose for moderate to severe pain in opioid-naive patients, 0.3 mg/kg q 3 – 4 hr initially.
• PO (Children >1 mo): Prompt-release tablets and solution, 0.2 – 0.5 mg/kg/dose q 4 – 6 hr as needed. Controlled-release tablet, 0.3 – 0.6 mg/kg/dose q 12 hr.
• IM, IV, Subcut (Children <50 kg): Usual starting dose for moderate to severe pain in opioid-naive patients, 0.05 – 0.2 mg/kg q 3 – 4 hr, maximum: 15 mg/dose.
• IV, Subcut (Children >1 mo): Continuous infusion, postoperative pain, 0.01 – 0.04 mg/kg/hr. Continuous infusion, sickle cell or cancer pain, 0.02 – 2.6 mg/kg/hr.
• Epidural (Children >1 mo): 0.03 – 0.05 mg/kg, maximum dose: 0.1 mg/kg or 5 mg/24 hr. Use preservative-free formulation.

Dosage for Adults

• PO, Rect (Adults ≥50 kg): Usual starting dose for moderate to severe pain in opioid-naive patients, 30 mg q 3 – 4 hr initially or once 24-hr opioid requirement is determined, convert to extended-release morphine by administering total daily oral morphine dose every 24 hr (as Kadian or other ER capsules), 50% of the total daily oral morphine dose every 12 hr (as Arymo ER, Kadian, Morphabond, MS Contin), or 33% of the total daily oral morphine dose every 8 hr (as Arymo ER, MS Contin). The dose of ER capsules (not Kadian) should not exceed 1600 mg/day because of the fumaric acid in the formulation.
• PO, Rect (Adults): Usual starting dose for moderate to severe pain in opioid-naive patients, 0.3 mg/kg q 3 – 4 hr initially.
• IM, IV, Subcut (Adults ≥50 kg): Usual starting dose for moderate to severe pain in opioid-naive patients, 4–10 mg q 3–4 hr. MI, 8–15 mg; for very severe pain additional smaller doses may be given every 3–4 hr.
• IM, IV, Subcut (Adults): Usual starting dose for moderate to severe pain in opioid-naive patients, 0.05 – 0.2 mg/kg q 3 – 4 hr, maximum: 15 mg/dose.
• IV, Subcut (Adults): Continuous infusion, 0.8 – 10 mg/hr; may be preceded by a bolus of 15 mg (infusion rates vary greatly; up to 80 mg/hr have been used).
• Epidural (Adults): Intermittent injection, 5 mg/day (initially); if relief is not obtained at 60 min, 1 – 2 mg increments may be made (total dose not to exceed 10 mg/day). Continuous infusion, 2 – 4 mg/24 hr; may increase by 1 – 2 mg/day (up to 30 mg/day).
• IT (Adults): 0.2 – 1 mg. Use preservative-free formulation.

Pharmacokinetics

1. Absorption. Absorbed orally, IV, IM, subcut, rectally, and transdermally. IV gives the fastest onset; oral is slower due to first-pass metabolism in the liver.
2. Distribution. Distributes via the bloodstream and crosses the blood-brain barrier to reach the CNS. Highly lipophilic, readily penetrating brain, lungs, liver, and kidneys.
3. Protein binding. Premature infants: <20%; adults: 35%.
4. Metabolism. Primarily hepatic, mainly glucuronidation by UDP-glucuronosyltransferase (UGT), producing morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). M6G has significant analgesic activity. Minor pathways include N-demethylation and sulfate conjugation.
5. Excretion. M3G, M6G, and a small fraction of unchanged morphine are excreted primarily by the kidneys; urinary excretion accounts for roughly 90% of a dose, with a small amount in feces. Renal impairment prolongs the elimination half-life.
6. Half-life. Premature neonates: 10 – 20 hr; neonates: 7.6 hr; infants 1 – 3 mo: 6.2 hr; children 6 mo – 2.5 yr: 2.9 hr; children 3–6 yr: 1–2 hr; children 6–19 yr with sickle cell disease: 1.3 hr; adults: 2 – 4 hr. M6G has a longer half-life than morphine, which prolongs the duration of action of some formulations.
7. Factors affecting pharmacokinetics. Age, hepatic function, renal function, genetic polymorphisms in metabolizing enzymes, concurrent drugs affecting hepatic enzymes or renal function, and individual variation in absorption and metabolism.

Nursing Considerations for Morphine

Nursing Assessment

1. Assess pain intensity, location, duration, and quality. Use a standardized tool (Numeric Rating Scale, Visual Analog Scale) for baseline data to judge effectiveness and guide further management.
2. Review medical history. Allergies, previous opioid use, concurrent medications, and comorbidities such as respiratory or renal impairment flag risk for adverse effects and interactions.
3. Monitor vital signs and respiratory status. Check respiratory rate, oxygen saturation, and level of consciousness before and after dosing; morphine can cause respiratory depression, especially in opioid-naive patients or those with respiratory disease.
4. Assess baseline sedation and alertness. Watch for over-sedation and adjust dose or frequency to limit respiratory depression.
5. Assess bowel habits. Frequency and consistency guide preventive measures (stool softeners, laxatives, dietary changes) for opioid-induced constipation.
6. Assess emotional well-being, social interactions, and functional status. A psychosocial assessment identifies coping, support, and barriers to adherence for holistic care.
7. Assess functional status, mobility, and pain-related limitations. Sets realistic goals and tracks functional improvement over time.
8. Assess health literacy and knowledge of morphine use. Tailor teaching on administration, side effects, and managing adverse reactions.
9. Monitor for common adverse effects (nausea, vomiting, pruritus, urinary retention, hypotension). Early management improves tolerability and continuity of therapy.
10. Assess geriatric patients frequently. Older adults are more sensitive to opioids and to respiratory complications.
11. Assess pediatric patients frequently. Children are more sensitive to opioids and may show respiratory complications, excitability, and restlessness.
12. Assess risk for opioid addiction, abuse, or misuse before administration. Crushing, chewing, snorting, or injecting dissolved extended-release product delivers an uncontrolled dose and can cause overdose and death.
13. Monitor laboratory values. Morphine may increase plasma amylase and lipase.

Nursing Diagnoses

1. Acute pain, commonly postoperative or trauma-related. Focus on assessing and managing pain and monitoring for adverse effects.
2. Potential respiratory compromise. Morphine can depress respiratory drive, causing hypoventilation or arrest in opioid-naive or high-risk patients. Monitor respiration, give oxygen as needed, and intervene promptly.
3. Risk for constipation. Use stool softeners, laxatives, fiber, and hydration to prevent opioid-induced constipation.
4. Risk for injury. Sedation and CNS depression raise fall risk. Use fall precautions, a safe environment, and frequent sedation checks.
5. Risk for infection. Prolonged opioid therapy can suppress immunity. Use hand hygiene, aseptic technique, and infection monitoring.
6. Deficient knowledge of dosing and side effects, addressed through education.

Nursing Interventions

1. Administer by the prescribed route, dose, and frequency, with accurate documentation and adherence to safety protocols. This minimizes dosing errors and delivers timely relief.
2. Implement preventive measures for opioid-induced constipation (OIC): stool softeners, laxatives, fiber, and hydration.
3. Implement fall prevention: bed in the lowest position, bed rails, assistance with ambulation, and a clutter-free environment. Morphine-induced sedation and dizziness raise fall risk, especially in elderly or debilitated patients.

Patient Education and Teaching

1. Teach morphine therapy: administration, side effects, signs of respiratory depression, and how to manage adverse reactions. This supports adherence and self-management.
2. Stress adherence to the dosing schedule and complementary strategies (relaxation, positioning, distraction) to enhance relief and patient autonomy.
3. Review common side effects (nausea, constipation, drowsiness, dizziness) and how to manage them, so patients anticipate rather than fear them.
4. Teach the signs of respiratory depression (slow or shallow breathing, difficulty breathing) and to seek immediate care if they occur.
5. Instruct on safe storage and proper disposal of unused or expired medication to prevent accidental ingestion, diversion, or misuse.
6. Stress regular followup appointments for ongoing pain assessment, medication evaluation, and dose adjustment.

Evaluation and Desired Outcomes

1. Pain relief. Pain reduced to a manageable level as reported by the patient (such as a pain score reduced by ≥ 2 points on a numeric rating scale).
2. Improved functional status. Greater independence in ADLs and fewer pain-related limitations.
3. Adequate pain control with minimal adverse effects. Comfort and safety maintained during therapy.
4. Patient satisfaction with pain relief, effectiveness, and overall care.
5. Compliance with the treatment plan, including medication schedules, followup appointments, and pain-management instructions.
6. Optimal bowel function, with effective management of opioid-induced constipation.

Frequently Asked Questions

What is morphine used for? Morphine is a potent opioid analgesic for moderate to severe pain, including postoperative, trauma, cancer, and palliative or end-of-life pain. It binds mu-opioid receptors in the brain and spinal cord to reduce pain perception, and in palliative care it also relieves dyspnea (StatPearls).

What is the most dangerous side effect? Life-threatening respiratory depression. It is most likely in opioid-naive patients, with high or escalating doses, and when combined with other CNS depressants such as benzodiazepines or alcohol. Monitor respiratory rate, oxygen saturation, and sedation closely at initiation and dose changes.

What reverses a morphine overdose? Naloxone, an opioid antagonist. Because morphine carries an FDA boxed warning for respiratory depression, the FDA recommends assessing every patient's need for naloxone access when starting and renewing therapy.

Why do nurses give a bowel regimen with morphine? Opioids slow gut motility, so constipation is common and does not improve with tolerance. Stool softeners or laxatives, fluids, fiber, and activity are often started prophylactically.

Is morphine a controlled substance? Yes. Morphine is a Schedule II controlled substance with high potential for misuse and dependence. Crushing, chewing, snorting, or injecting an extended-release product delivers an uncontrolled dose and can cause fatal overdose; assess misuse risk and teach safe storage and disposal.

Who needs extra caution with morphine? Older adults and very young children are more sensitive to opioids and to respiratory complications, and patients with renal impairment retain the active metabolite M6G, which prolongs effects. Avoid use with MAOIs (or within 14 days of stopping them) because of serotonin syndrome risk.